US Department of Defense awards $2.2 M CDN research contract toTwinstrand Therapeutics Inc.
Development of medical countermeasure to ricin
Advertisement
Twinstrand Therapeutics announced that it has been awarded a contract for research and development of a human polyclonal antibody (antidote) to ricin poisoning. The two-year $2.2 M CDN ($1.9 M USD) contract was granted, in a competitive process, by the United States Defense Threat Reduction Agency Joint Science and Technology Office for Chemical and Biological Defense.
Dr. Thor Borgford, Twinstrand President & CEO, commented "This award is an important recognition of Twinstrand's growing clinical and drug development capabilities. Importantly, we expect the program will lead the company to a significant product opportunity. It is worth noting further that Twinstrand is able to leverage pre-existing therapeutic assets in the development of the countermeasure that make the program an ideal complement to our oncology drug platform."